In Good Company

In Good Company: Medidata's de Vries eyes bullet-drugs era

The firm has grown as a dominant provider of Web-based data solutions for clinical trials

Maybe, it was all in the genes.

When Glen de Vries was growing up in New York, his big dream was to be a scientist. As a child, he wanted to be a physicist. As he grew older, that turned to wanting to be a chemist and, by the time he was in university, the computer nerd had decided that to be a biologist was to be his calling.

Please or to continue reading the full article.

Get unlimited access to all stories at $0.99/month

  • Latest headlines and exclusive stories
  • In-depth analyses and award-winning multimedia content
  • Get access to all with our no-contract promotional package at only $0.99/month for the first 3 months*

*Terms and conditions apply.

A version of this article appeared in the print edition of The Sunday Times on February 03, 2019, with the headline 'Medidata's de Vries eyes bullet-drugs era'. Subscribe